drugset / Trial / NCT03752463
NMDA Enhancer for the Treatment of Mild Alzheimer's Disease
Phase 2
Completed
154 enrolled
Chang Gung Memorial Hospital
Ministry of Science and Technology, Taiwan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors (NMDAR) were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease (AD). This study is a randomized, double-blind, placebo controlled drug trial for testing the efficacy of NMDAR-enhancer. All subjects will be allocated randomly to 4 groups: (1) DAOI-A group; (2) DAOI-B group; (3) DAOI-C group; (4) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOI may yield better efficacy than placebo for cognitive function in patients with AD.
Timeline
- Start
- 2015-05-22
- Primary completion
- 2021-07-31
- Completion
- 2021-07-31
Publications
- Lin CH, Lane HY. Sodium benzoate treatment decreased amyloid beta peptides and improved cognitive function among patients with Alzheimer's disease: secondary analysis of a randomized clinical trial. Transl Psychiatry. 2025 Aug 5;15(1):264. doi: 10.1038/s41398-025-03492-3.
- Lane HY, Wang SH, Lin CH. Sex- and dose-dependent catalase increase and its clinical impact in a benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease. Pharmacol Biochem Behav. 2024 Dec;245:173885. doi: 10.1016/j.pbb.2024.173885. Epub 2024 Oct 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Benzoate | Small molecule | 500 mg | Oral |
| Subject | Sodium Benzoate | Small molecule | 750 mg | Oral |
| Subject | Sodium Benzoate | Small molecule | 1000 mg | Oral |